CD276 and neoplasm: Here, we expand on the idea, introducing a novel tumor-targeting anti-B7-H3 Fab and NK checkpoint-inhibiting anti-TIGIT Fab, resulting in a novel dual NK cell-targeting natural killer engager antibody (Figure 1).